Objective: The pathogenesis of keloid is largely unknown. Because keloid and atopic dermatitis have overlapping pathophysiological mechanisms, we aimed to evaluate keloid risk in patients with atopic dermatitis.
Study Design: Population-based retrospective cohort study.
Setting: The Taiwan National Health Insurance Research Database was used to analyse data for people who had been diagnosed with atopic dermatitis.
Participants: We identified 8371 patients with newly diagnosed atopic dermatitis during 1996-2010. An additional 33 484 controls without atopic dermatitis were randomly identified and frequency matched at a one-to-four ratio.
Primary And Secondary Outcome Measure: The association between atopic dermatitis and keloid risk was estimated using Cox proportional hazard regression models.
Results: After adjustment for covariates, the atopic dermatitis patients have a 3.19-fold greater risk of developing keloid compared with the non-atopic dermatitis group (3.19vs1.07 per 1000 person-years, respectively). During the study period, 163 patients with atopic dermatitis and 532 patients without atopic dermatitis developed keloid. Notably, keloid risk increased with severity of atopic dermatitis, particularly in patients with moderate to severe atopic dermatitis.
Conclusions: Our results indicate that patients with atopic dermatitis had a higher than normal risk of developing keloid and suggest that atopic dermatitis may be an independent risk factor for keloid.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059319 | PMC |
http://dx.doi.org/10.1136/bmjopen-2018-022865 | DOI Listing |
Int J Biol Macromol
January 2025
Department of Dermatology, the Affiliated Hospital of Guilin Medical University, Guilin Medical University, Guilin, China. Electronic address:
Many atopic dermatitis (AD) patients have suboptimal responses to Dupilumab therapy. This study identified key genes linked to this resistance using multi-omics approaches to benefit more patients. We selected a prospective cohort of 54 CE treated with Dupilumab from the GEO database.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
School of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan; PhD Program in Pharmaceutical Biotechnology, Fu Jen Catholic University, New Taipei City 24205, Taiwan; School of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. Electronic address:
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by itching and redness, affecting individuals of all ages and significantly impairing their quality of life. The prevalence of AD is rising, posing serious health concern. Relief of itching is a primary treatment objective; however, steroid treatments can lead to adverse effects, including skin barrier thinning.
View Article and Find Full Text PDFJ Dermatol
January 2025
Department of Dermatology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab.
View Article and Find Full Text PDFSisli Etfal Hastan Tip Bul
December 2024
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Objectives: Atopic skin plays a significant etiological role in the development of prurigo nodularis (PN). In addition to atopic dermatitis (AD), atopic skin diathesis without eczema can also contribute to the development of PN due to its association with itching. This study aims to evaluate PN in terms of AD/atopic skin diathesis, associated comorbidities, and clinical findings.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Małopolska Centre of Biotechnology, Stem Cell Laboratory, Jagiellonian University, Kraków, Poland.
Objective: To present and analyze eight clinical cases illustrating the use of rose stem cell-derived exosomes (RSCEs) in treating various dermatological conditions and to review current literature on plant-derived exosomes in medicine and dermatology.
Background: RSCEs possess low cytotoxicity, high biocompatibility, and effective cellular uptake, making them promising agents for dermatological therapies. A literature review included in the introduction and discussion covers the broader role of plant-derived exosomes, highlighting their therapeutic potential in skin treatment.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!